Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma - Université de Bourgogne Accéder directement au contenu
Article Dans Une Revue Blood Année : 2018

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Aurore Perrot
  • Fonction : Auteur
  • PersonId : 769019
  • IdRef : 139420215
Laurent Garderet
Chantal Doyen
  • Fonction : Auteur
Mohamad Mohty
Victoria Carlton
  • Fonction : Auteur
Martin Moorhead
  • Fonction : Auteur
Tom Willis
  • Fonction : Auteur
Malek Faham
  • Fonction : Auteur
Kenneth C. Anderson
  • Fonction : Auteur

Résumé

The introduction of novel agents has led to major improvements in clinical outcomes for patients with multiple myeloma. To shorten evaluation times for new treatments, health agencies are currently examining minimal residual disease (MRD) as a surrogate end point in clinical trials. We assessed the prognostic value of MRD, measured during maintenance therapy by next-generation sequencing (NGS). MRD negativity was defined as the absence of tumor plasma cell within 1 000 000 bone marrow cells (<10-6). Data were analyzed from a recent clinical trial that evaluated the role of transplantation in newly diagnosed myeloma patients treated with lenalidomide, bortezomib, and dexamethasone (RVD). MRD negativity was achieved at least once during maintenance in 127 patients (25%). At the start of maintenance therapy, MRD was a strong prognostic factor for both progression-free survival (adjusted hazard ratio, 0.22; 95% confidence interval, 0.15-0.34; P < .001) and overall survival (adjusted hazard ratio, 0.24; 95% confidence interval, 0.11-0.54; P = .001). Patients who were MRD negative had a higher probability of prolonged progression-free survival than patients with detectable residual disease, regardless of treatment group (RVD vs transplant), cytogenetic risk profile, or International Staging System disease stage at diagnosis. These results were similar after completion of maintenance therapy. Our findings confirm the value of MRD status, as determined by NGS, as a prognostic biomarker in multiple myeloma, and suggest that this approach could be used to adapt treatment strategies in future clinical trials.

Domaines

Cancer

Dates et versions

hal-02006039 , version 1 (04-02-2019)

Identifiants

Citer

Aurore Perrot, Valérie Lauwers-Cances, Paul Corre, Nelly Robillard, Cyrille Hulin, et al.. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood, 2018, 132 (23), pp.2456-2464. ⟨10.1182/blood-2018-06-858613⟩. ⟨hal-02006039⟩
118 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More